Literature DB >> 2867341

Rifabutine inhibits HTLV-III.

R Anand, J Moore, P Feorino, J Curran, A Srinivasan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2867341     DOI： 10.1016/s0140-6736(86)90747-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

2.  Pharmacokinetics of rifabutin.

Authors:  M H Skinner; M Hsieh; J Torseth; D Pauloin; G Bhatia; S Harkonen; T C Merigan; T F Blaschke
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

3.  Interaction between rifabutin and human immunodeficiency virus type 1: inhibition of replication, cytopathic effect, and reverse transcriptase in vitro.

Authors:  R Anand; J L Moore; J W Curran; A Srinivasan
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 4.  Antiviral therapy in human immunodeficiency virus infection.

Authors:  E Sandström
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.